Picture loading failed.

Anti-CA9 therapeutic antibody (Pre-made Girentuximab biosimilar,Whole mAb Radiolabelled) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Girentuximab (trade name Rencarex) is a chimeric IgG1 monoclonal antibody to carbonic anhydrase IX (CAIX).[1] CAIX is expressed on the surface of most renal cancer cells and is hypothesized to be on the surface of other tumor cells. It is investigational agent in clinical trials for renal cell carcinoma. Its development was suspended as a "naked" or unconjugated antibody during phase III trials due to efficacy.

Order informatioin


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-245-1mg 1mg Inquiry
GMP-Bios-ab-245-10mg 10mg Inquiry
GMP-Bios-ab-245-100mg 100mg Inquiry
GMP-Bios-ab-245-xmg ≥100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Anti-CA9 therapeutic antibody (Pre-made Girentuximab biosimilar,Whole mAb Radiolabelled)
INN Name Girentuximab
TargetCA9
FormatWhole mAb Radiolabelled
DerivationChimeric (Mouse/Human)
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-III
Est. StatusDiscontinued
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2009
Year Recommended2010
CompaniesCentocor Inc;Heidelberg Pharma AG
Conditions Approvedna
Conditions Activena
Conditions DiscontinuedRenal cancer
Development Techna